Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic

Fig. 1

Overview of the Gilenya@Home FDO and in-clinic procedures. a Healthcare professionals were directed to measure vital signs (including blood pressure and heart rate) at baseline and then a minimum of once every hour throughout the rest of the procedure, although vital signs can be recorded more frequently, and for up to 10 h if needed. bSyncope, near syncope, loss of consciousness, nausea, emesis, chest pain, or shortness of breath. cIschemic heart disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, cerebrovascular disease, uncontrolled hypertension, history of symptomatic bradycardia, history of recurrent syncope, severe untreated sleep apnea, AV block, sinoatrial block. AV atrioventricular, BP blood pressure, bpm beats per minute, ECG electrocardiogram, ER emergency room, FDO first-dose observation, HR heart rate, hr hour, ms millisecond, QTc corrected QT interval

Back to article page